Ibrance 125 mg is prescribed by an oncologist for the treatment of locally advanced or metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer: 🔹 In combination with an aromatase inhibitor: As first-line endocrine therapy in postmenopausal women. 🔹 In combination with fulvestrant: In women whose disease has progressed after prior hormonal therapy.

Dosage and administration

Sales Form: 1 bottle contains 21 capsules of 125 mg (designed for one full course/cycle).⚠️ INSTRUCTIONS FOR USE: Cyclic Regimen: The standard dosing schedule is 1 capsule (125 mg) once daily for 21 consecutive days, followed by a mandatory 7-day break (21/7 cycle). Method: The capsule should be taken with food (this ensures stable drug concentration), preferably at the same time each day. The capsule must not be opened or chewed. Blood Monitoring: Before starting each cycle and in the middle of the first few cycles, a complete blood count is necessary to monitor neutrophil levels (white blood cells). Storage: Store at 15–30°C in the original packaging.

⛔ Individual Intolerance: Hypersensitivity to palbociclib. ⛔ Pregnancy and Lactation: The drug can cause fetal harm. Strictly contraindicated. Reliable contraception must be used during and for 3 weeks after treatment. ⛔ Age: Not used for the treatment of children and adolescents under 18 years of age. ⛔ Interactions: Do not consume grapefruit or grapefruit juice during treatment, as they can significantly increase the drug level in the blood and cause toxicity. ⛔ Infections: Severe active infectious diseases.

When using Ibrance 125 mg, the most common observations are changes in the hematopoietic system: 🩸 Neutropenia: Decrease in neutrophil levels (observed in most patients, but usually managed by a treatment break). Anemia and thrombocytopenia are also possible. 💪 General Symptoms: Increased fatigue, weakness, dizziness. 🤢 Digestion: Nausea, diarrhea, stomatitis (mouth sores), decreased appetite. 💇♀️ Appearance: Thinning or partial loss of hair (alopecia), dry skin, rash. ⚠️ Important: If a fever develops or signs of a cold appear while taking the medication, contact your treating physician immediately.

Ibrance 125 — Palbociclib 125 mg, 21 pcs, Pfizer

100% original product

Active ingredient

Palbociclib

Manufacturer

Pfizer

Dosage 125 mg

Dosage form Capsules

Capsules per pack 21

Ibrance 125 — Palbociclib 125 mg (21 Capsules)

Name: Ibrance 125
Brand: Pfizer
SKU: PROD-288
Price: 44145 UAH
Availability: InStock

44145₴ ~~48559₴~~ -9% On order · from 7 days

Ibrance 125 mg (Palbociclib) is an innovative targeted medication used to treat specific types of metastatic breast cancer. Palbociclib is a first-in-class inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). By blocking these proteins, the drug slows the division of tumor cells and prevents disease progression, significantly increasing progression-free survival when used in combination with hormonal therapy.

Manufacturer: Pfizer, USA. Ibrance has made a breakthrough in oncology, becoming a standard of therapy for patients with hormone-receptor-positive cancer, allowing for long-term disease control while maintaining quality of life.

Key Features:

✅ Cycle Control Mechanism: Selectively blocks the transition of cancer cells from the resting phase to the division phase.
✅ Synergy with Hormone Therapy: Enhances the effect of aromatase inhibitors and fulvestrant, overcoming tumor resistance.
✅ Convenience of Use: The oral form in a 125 mg dosage is the standard starting dose for most patients.

Ibrance 125 mg is prescribed by an oncologist for the treatment of locally advanced or metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer:

🔹 In combination with an aromatase inhibitor: As first-line endocrine therapy in postmenopausal women.
🔹 In combination with fulvestrant: In women whose disease has progressed after prior hormonal therapy.

Sales Form: 1 bottle contains 21 capsules of 125 mg (designed for one full course/cycle).

⚠️ INSTRUCTIONS FOR USE:

Cyclic Regimen: The standard dosing schedule is 1 capsule (125 mg) once daily for 21 consecutive days, followed by a mandatory 7-day break (21/7 cycle).
Method: The capsule should be taken with food (this ensures stable drug concentration), preferably at the same time each day. The capsule must not be opened or chewed.
Blood Monitoring: Before starting each cycle and in the middle of the first few cycles, a complete blood count is necessary to monitor neutrophil levels (white blood cells).
Storage: Store at 15–30°C in the original packaging.

⛔ Individual Intolerance: Hypersensitivity to palbociclib.
⛔ Pregnancy and Lactation: The drug can cause fetal harm. Strictly contraindicated. Reliable contraception must be used during and for 3 weeks after treatment.
⛔ Age: Not used for the treatment of children and adolescents under 18 years of age.
⛔ Interactions: Do not consume grapefruit or grapefruit juice during treatment, as they can significantly increase the drug level in the blood and cause toxicity.
⛔ Infections: Severe active infectious diseases.

When using Ibrance 125 mg, the most common observations are changes in the hematopoietic system:

🩸 Neutropenia: Decrease in neutrophil levels (observed in most patients, but usually managed by a treatment break). Anemia and thrombocytopenia are also possible.
💪 General Symptoms: Increased fatigue, weakness, dizziness.
🤢 Digestion: Nausea, diarrhea, stomatitis (mouth sores), decreased appetite.
💇‍♀️ Appearance: Thinning or partial loss of hair (alopecia), dry skin, rash.
⚠️ Important: If a fever develops or signs of a cold appear while taking the medication, contact your treating physician immediately.